This presentation describes a study by MMV and local partners in Uganda, conducted in June-September 2007. The key findings were as follows: (1) recommended antimalarial treatment was provided free in the public/mission facilities, but was not always available; (2) in the private sector, artemisinin combination therapies (ACTs) were many times more expensive than the older ineffective medicines; (3) complete courses of all antimalarial medicines were unaffordable to a significant proportion of the population; (4) families had to choose between basic needs like food and education, or purchasing medicines for the treatment of malaria; (5) components of the final patient price (e.g. manufacturer's selling price, supply chain mark-ups) were very different for different types of medicines in different types of outlet; and (6) the study provided an evidence base to guide initiatives to replace older ineffective medicines with ACTs.
Mutambi, R.; Auton,; M. Understanding the Antimalarials Market in Uganda. Presented at The antimalarials market in Africa - do we know enough? Symposium held at the American Society of Tropical Medicine and Hygiene meeting, New Orleans, Louisiana, USA, 8 December 2008. Medicines For Malaria Venture, Geneva, Switzerland (2008) 20 pp.
Understanding the Antimalarials Market in Uganda